Content area

|
|

Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

Et superficielt spredende melanom.
Forfatter(e)
Tessa Bystrup Boyles1, Inge Marie Svane2, Lars Bastholt3 & Henrik Schmidt1 1) Onkologisk Afdeling, Aarhus Universitetshospital 2) Center for Cancer og Immunterapi, Herlev Hospital 3) Onkologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2016;178:V02160126
Reference: 
Ugeskr Læger 2016;178:V02160126
Blad nummer: 
Sidetal: 
2-5
Treatment of BRAF-mutated metastatic melanoma
Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was con­sidered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the com­bi­n­ation of the inhibitors, many patients develop acquired resistance within a year.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af David McWhan | 27/11
4 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Jan Nielsen | 23/11
1 Kommentar
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar
af Niels Holmark Andersen | 20/11
1 Kommentar